Edwards hails "excellent" aortic valve trial

• Edwards Lifesciences (NYSE:EW) says the outcomes at 30 days in a trial of its Sapien 3 transcatheter aortic valve were "excellent."
• Immortality was a "very low" 2.1% and the stroke rate was 1%, while there were few access-site complications. Over 96% of patients had a mild paravalvular leak, although there was no severe suh leaks.
• The results relate to 150 high- and intermediate-risk patients. (PR)
• See Edwards and Medtronic settle patent fight